Administration of estrogen as a treatment of patients with prostatic carcinoma has been correlated with an increase in the frequency of cardiovascular complications. The purpose of the present autopsy investigation was to study the incidence of pulmonary embolism, and to ascertain whether any relationship existed between this incidence and estrogen treatment. Reports of autopsies and clinical records of patients with prostatic cancer in all stages who died at the Malmö General Hospital from 1973 to 1982 were individually reviewed. The incidence of pulmonary embolism serious or not serious was recorded. Thromboembolic risk factors have been registered: stage of the tumor, other malignant disease, age and weight of the patient, duration of bed rest and operation before death, and, finally, type and duration of estrogen treatment. The role of treatment with diethylstilbestrol diphosphate as a thromboembolic risk factor will be discussed.

Keywords:
Pulmonary embolism, Estrogen treatment, Prostatic carcinoma
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.